Kevin M. Sullivan, MD, Discusses Treatment Expansion in Lung Cancer

Article

Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.

Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treating patients with lung cancer have expanded in the past several years at the Annual New York Lung Cancers Symposium®.

Transcription:
There’s a lot of exciting things about being a thoracic medical oncologist. The options for treating our patients have expanded so greatly in the past several years and it’s an exciting time as just, it seems like every day, just more and more information is coming out about ways to not only diagnose and work up our patients, but to find the most appropriate treatment that has the highest chance of success in treating our patients. And even those patients that develop resistance that progress on a certain therapy, we have more and more options for them coming down the line, so it’s an exciting time to be able to help and benefit our patients.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content